My Profile

Search abstracts

Lewis Sheiner


2014
Alicante, Spain



2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 16 (2007) Abstr 1218 [www.page-meeting.org/?abstract=1218]


PDF poster/presentation:
Click to openClick to open

Poster: Applications- Other topics


Mark Peterson Calcium Homeostasis and Bone Remodeling: Development of an Integrated Model for Evaluation and Simulation of Therapeutic Responses to Bone-Related Therapies

M.C. Peterson(1), M.M. Riggs(2)

(1)Amgen Inc., Thousand Oaks, CA USA, (2)Metrum Research Group, LLC, Tariffville, CT USA

Objectives: Calcium (Ca) homeostasis and bone remodeling are complexly integrated, highly regulated processes involving multiple organs and endocrine pathways. Published attempts to develop a generalized model have failed to provide an adequate platform for describing multiple therapeutic class effects on the system. We describe the development of a model that characterizes and predicts longitudinal Ca homeostasis and related co-factors (including phosphate, PTH and calcitriol), as well as expected rates of bone turnover due to natural progression, therapeutic intervention, or disease states. 

Methods: Our approach is based on physiologic requirements to maintain Ca balance with the general model predicated on 3 manuscripts [1-3]. Significant modifications and additional feedback mechanisms, based on literature reports and Amgen internal data, have been added to appropriately integrate the model. The model includes the RANK-RANKL-OPG system to enable characterization of osteoclast (OC) and osteoblast (OB) genesis and survival. PTH-mediated anti-apoptotic signaling in OB allows for description of both anabolic and catabolic effects of PTH on bone remodeling. TGFbeta-mediated feedback mechanisms are incorporated to capture homeostatic observations. The model has enabled evaluation of various affecting mechanisms and ramifications of therapeutic interventions and disease states, including the following: (1) OPG infusion, (2) intermittent- and (3) constant-PTH infusion, (4) hyper- and (5) hypo-calcemia, and (6) progressive renal insufficiency.

Results: The integrated model appears to provide a generalizable structure with known or plausible cell signaling concepts and physiologically consistent parameters.  Model predictions under conditions (1) - (6) provide results consistent with clinical observations. 

Conclusion: We have developed a robust physiologic model that provides continuous descriptions of biomarkers and electrolytes including calcium, phosphate, PTH, and markers of bone turnover consistent with literature and Amgen internal data. This model may allow for investigation of therapeutics under development, prediction of cytokine mediators of bone homeostasis, and provide a platform for hypothesis testing prior to clinical investigations.

References:
[1]Raposo et. al, J Clin Endocrin Metab, 2002; 87(9):4330-40.
[2] Lemaire et. al, J Theor Biol, 2004; 229(3):293-309.
[3] Bellido et. al, J Biological Chem, 2003; 278(50):50259-72.